Yoshino, Takayuki

写真a

Affiliation

School of Medicine, Center for Global Advanced Medical Research and Development ( Shinanomachi )

Position

Professor

Contact Address

東京都新宿区信濃町35　総合医科学研究棟5階5N5

Telephone No.

03-5315-4372

Fax No.

03-5843-6992
Page Top ▲

Career 【 Display / hide 】

  • 1995
    -
    1997

    防衛医科大学校病院, 研修医

  • 1997
    -
    1999

    国立がんセンター中央病院, 臨床検査部・病理部, 研修医

  • 1999
    -
    2001

    国立がんセンター東病院, 内視鏡部消化器内科, 研修医

  • 2001
    -
    2002

    国立がんセンター東病院, 内視鏡部消化器内科, 非常勤医師

  • 2002
    -
    2007.07

    静岡県立静岡がんセンター, 消化器内科, 副医長

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 1989
    -
    1995

    National Defense Medical College

    University, Graduated

  • 2005

    Mayo Clinic, college of medicine，Vanderbilt-Ingram Cancer Center，Dana-Farber Cancer Institute, 留学

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, Kagawa University, Coursework, 2017.07

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Tumor diagnostics and therapeutics

Page Top ▲
 

Books 【 Display / hide 】

Page Top ▲

Papers 【 Display / hide 】

  • Association between light exposure and sleep problems related to nocturia in older adults: the Nagahama study

    Nakamoto I., Uiji S., Negoro H., Yoshino T., Horita S., Setoh K., Tabara Y., Murase K., Minami T., Matsumoto T., Nakatsuka Y., Hamada S., Takahashi N., Komenami N., Matsuda F., Chin K., Wakamura T.

    Journal of Physiological Anthropology 45 ( 1 )  2026.12

    ISSN  18806791

    　View Summary

    Background: The prevalence of nocturia-related sleep problems is higher in older people. This study investigated whether morning and evening light exposure is associated with the sleep problems related to objectively identified nocturnal urination in community-dwelling older adults. Methods: This cross-sectional study analyzed data collected between 2013 and 2016 for the Nagahama Prospective Cohort for Comprehensive Human Bioscience (the Nagahama Study). The study included 1585 participants aged ≥ 65 years who met the criteria for inclusion in the present analysis. An actigraph was used to measure sleep, nocturnal voiding time, and light exposure. The frequency of nocturnal voiding was derived from self-reported entries in the participants’ sleep diaries. Morning light (ML) exposure was defined as the period between waking and 12:00, while evening light (EL) exposure was defined as the period between 18:00 and bedtime. The first uninterrupted sleep period (FUSP) was calculated as the interval between the sleep onset time and the first nocturnal void. Additionally, the ratio of FUSP to sleep period time (FUSP/SPT) was calculated. Associations between light exposure parameters and the frequency of nocturnal voiding, FUSP, or FUSP/SPT were examined using multivariable linear regression models. Results: Of the 1585 participants, 38.7% were male median age was 70 years. The median nocturnal voiding frequency was 1.0 times (IQR: 0.4, 1.4) and the median FUSP was 4.6 h (IQR: 3.2, 5.9). In multivariable linear regression, log ML exposure was significantly associated with FUSP and FUSP/SPT (B = 0.17, 95% CI: 0.02, 0.32; B = 2.20, 95% CI: 0.26, 4.14, respectively). In contrast, the duration of ML exposure ≥ 1,000 lx, EL exposure, and the duration of EL exposure ≥ 50 lx were not significantly associated with the frequency of nocturnal voiding, FUSP or FUSP/SPT. Conclusions: Greater morning light exposure was associated with a longer FUSP. Morning bright light exposure may therefore help delay nocturia-related sleep interruptions, potentially contributing to improved sleep quality among older people.

  • Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models

    Hara T., Morimoto M., Kakehi M., Kamedani M., Nakayama M., Yamamoto S., Osaka T., Soeda J., Bando H., Yoshino T.

    BMC Cancer 26 ( 1 )  2026.12

    　View Summary

    Background: The combination of bevacizumab and TAS-102 has emerged as a treatment option for metastatic colorectal cancer (CRC). Bevacizumab is an anti-VEGF-A antibody, and TAS-102 is a cytotoxic nucleotide analog. Recently, fruquintinib, an oral, potent and highly selective inhibitor of all three vascular endothelial growth factor receptors (VEGFRs), has been approved for the treatment of chemorefractory CRC. The purpose of this study was to investigate the combined antitumor activity of fruquintinib and TAS-102 in CRC and gastric cancer (GC) models and to reveal possible mechanisms to explain the combined effects. Methods: In vitro angiogenic and lymphangiogenic activities were studied by tube formation assays using HUVECs and HDLECs, respectively. Protein expression was measured by Western blot analysis. Intratumor drug concentrations were determined by liquid chromatography-tandem mass spectrometry analysis. Antitumor activity was studied in xenograft models. Results: Fruquintinib inhibited tube formation in both HUVECs and HDLECs. Trifluridine, an anti-neoplastic component of TAS-102, potentiated the inhibition of tube formation by fruquintinib in HUVECs but not in HDLECs. Suppression of VEGFR downstream signaling, together with induction of DNA damage response, was observed in HUVECs treated with the fruquintinib plus trifluridine combination. In an HT-29 CRC xenograft model, the intratumor levels of trifluridine and its active metabolites were higher following the fruquintinib plus TAS-102 combination treatment than following TAS-102 monotherapy. Antitumor studies demonstrated that the combination of fruquintinib and TAS-102 suppressed tumor growth more potently than individual agents in HT-29 and COLO-205 CRC xenograft models. The combined effect was comparable to that of bevacizumab plus TAS-102 in CRC models and was also observed in SC-2-JCK and MKN45 GC xenograft models. The addition of fruquintinib did not increase body weight loss caused by TAS-102 alone. Conclusions: The combination of fruquintinib and TAS-102 improved antitumor activity in CRC and GC xenograft models, with in vitro evidence of enhanced anti-angiogenic activity of fruquintinib by trifluridine and ex vivo evidence of an increased amount of intratumor trifluridine with fruquintinib. Our data support testing the combination of fruquintinib and TAS-102 in clinical studies.

  • Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection

    Hidekazu Oyoshi, Hideaki Bando, Riu Yamashita, Shun-Ichiro Kageyama, Yoshiaki Nakamura, Satoshi Horasawa, Masaki Nakamura, Takeshi Fujisawa, Kento Tomizawa, Atsushi Motegi, Hidehiro Hojo, Hidenari Hirata, Hiroki Yukami, Saori Mishima, Daisuke Kotani, Masaaki Miyo, Koji Ando, Jun Watanabe, Naoya Akazawa, Kozo Kataoka, Hiroya Taniguchi, Eiji Oki, Ichiro Takemasa, Takeshi Kato, Masaki Mori, Adham Jurdi, Minetta C. Liu, Toshihiro Misumi, Sadatomo Zenda, Takayuki Yoshino

    npj Precision Oncology (Springer Science and Business Media LLC)  10 ( 1 )  2026.12

    ISSN  2397-768X

    　View Summary

    Abstract

    Circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC) has demonstrated clinical significance in various contexts, including post-curative resection. Therefore, we developed a predictive model integrating preoperative ctDNA levels with radiographic imaging to assess the risk of postoperative recurrence in patients with CRC. Patients with CRC from the GALAXY study with either newly diagnosed or recurrent, curatively resectable liver or lung metastases were enrolled between May 2020 and December 2022, and radiographic images were collected between February 2023 and January 2025. The ratio of preoperative ctDNA levels to tumor metastasis volume from radiographic imaging, ctDNA levels alone, and tumor volume alone was assessed. Overall, 181 and 48 patients from the GALAXY trial had liver and lung metastases, respectively. Among patients with liver metastases, the median progression-free survival (PFS) was 11.4 and 24 months in the high- and low-risk groups classified by the ctDNA model, respectively. Among patients with lung metastases, the median PFS was 12 months and not reached in the high- and low-risk groups classified by the ctDNA/volume model, respectively. Conclusively, incorporating radiological markers of necrosis and refining the tumor volume estimation may further improve model accuracy in liver metastasis settings.

  • Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis.

    Binbin Zheng-Lin, Taro Shibuki, Heidi E Kosiorek, Oluseyi Abidoye, Cody R Eslinger, Yasuyuki Kawamoto, Ryne C Ramaker, Shinji Itoh, Tadayoshi Hashimoto, Takao Fujisawa, Mitsuho Imai, Angelo Pirozzi, Celine Hoyek, Mohamad B Sonbol, Christina Wu, Nguyen H Tran, Hani Babiker, Lewis R Roberts, Ashley N Moyer, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshino, Makoto Ueno, Chigusa Morizane, Daniel H Ahn, Madhuri Gottam, Mitesh J Borad, John H Strickler, Masafumi Ikeda, Tanios Bekaii-Saab

    NPJ precision oncology 10 ( 1 )  2026.12

    ISSN  2397-768X

    　View Summary

    The prognosis of advanced biliary tract cancer remains poor despite up to 40% of tumors harboring actionable molecular alterations. This international collaborative study from Mayo Clinic, Duke Cancer Institute, National Cancer Center East (Japan), and the SCRUM-Japan GOZILA/MONSTAR-SCREEN projects evaluated clinical outcomes in 1049 patients with advanced BTC based on tumor molecular profiling and matched treatment selection. Patients were categorized into non-actionable, actionable with matched targeted therapy (matched), and actionable without matched therapy (unmatched) groups. Among 358 patients (34.1%) with actionable alterations, 160 (44.7%) received matched therapy. The matched group demonstrated significantly longer median overall survival (23.3 months; 95% CI: 19.5-30.4) compared to unmatched (14.7 months; 95% CI: 12.8-17.9) and non-actionable groups (17.1 months; 95% CI: 15.5-18.7; HR 0.57, 95% CI: 0.46-0.71; p 0.0001). In 700 patients receiving ≥2 lines of therapy, matched therapy remained independently associated with improved survival (HR 0.62; 95% CI 0.43-0.90). Notably, patients with actionable tumors who did not receive matched therapy experienced worse outcomes than those with non-actionable disease. These findings highlight the critical need for universal molecular profiling and equitable access to targeted therapies in advanced BTC.

  • Integrating east Asian traditional medicine into National Dementia care: A comparative policy analysis of China, Japan, and South Korea.

    Kwon CY, Shen C, Yoshino T, Lee J, Han Y

    Integrative medicine research 15 ( 3Part A ) 101290 2026.09

    ISSN  2213-4220

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • The Q-MONSTAR consortium: advancing fault-tolerant quantum computing for precision oncology.

    Mitsuho Imai, Riu Yamashita, Takao Fujisawa, Hiroki Sokuoka, Izumi Miki, Yasutoshi Sakamoto, Toshihiro Misumi, Borna Zandkarimi, Philipp T Ernst, Hideaki Bando, Takayuki Yoshino

    Nature medicine 32 ( 6 ) 1946 - 1947 2026.06

    ISSN  10788956

  • 局所進行直腸癌に対するTNT療法の多施設共同前向き第II相試験　ENSEMBLE-2試験の長期成績

    安藤 幸滋, 賀川 義規, 渡邉 純, 西沢 佑次郎, 植村 守, 諏訪 雄亮, 奥谷 浩一, 三代 雅明, 坂東 英明, 吉野 孝之, 沖 英次

    日本大腸肛門病学会雑誌 ((一社)日本大腸肛門病学会)  79 ( 6 ) 291 - 291 2026.06

    ISSN  0047-1801

  • Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery A Prospective Cohort Study: Erratum.

    Koji Ando, Atsushi Hamabe, Yoshiaki Nakamura, Jun Watanabe, Keiji Hirata, Kozo Kataoka, Masaaki Miyo, Kentaro Kato, Naoya Akazawa, Yoshinori Kagawa, Mitsuru Yokota, Kentaro Yamazaki, Saori Mishima, Hiroki Yukami, Daisuke Kotani, Hideaki Bando, George Laliotis, Shruti Sharma, Charuta C Palsuledesai, Matthew Rabinowitz, Adham Jurdi, Minetta C Liu, Alexey Aleshin, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Takayuki Yoshino, Eiji Oki

    Annals of surgery 283 ( 5 ) e7 2026.05

    ISSN  00034932

  • The MONSTAR-SCREEN-3 Spatial Atlas: Pan-cancer TME archetypes and clinically relevant tumor-immune ecosystems

    Mitsuho Imai, Eun Seop Seo, Jiyeon Hyeon, Shingo Sakashita, Yuka Nakamura, Tadayoshi Hashimoto, Shin Kobayashi, Jun Yuda, Riu Yamashita, Taro Shibuki, Takao Fujisawa, Masataka Amisaki, Kensuke Matsuda, Shun-ichiro Kageyama, Michiko Nagamine, Takeshi Kuwata, Hideaki Bando, Woong-Yang Park, Takayuki Yoshino

    CANCER RESEARCH 86 ( 7 )  2026.04

    ISSN  0008-5472

  • 大腸癌におけるトランスレーショナルリサーチの最前線　リキッドバイオプシーによるTNT後治療戦略の最適化(Translational Research in Colorectal Cancer: Bridging Bench and Bedside　Clinical Utility of ctDNA After Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Results from ENSEMBLE-1 and ENSEMBLE-2)

    賀川 義規, 渡邉 純, 安藤 幸滋, 植村 守, 伊澤 直樹, 奥谷 浩一, 松橋 延壽, 武藤 理, 本坊 拓也, 金城 達也, 諏訪 雄亮, 西沢 佑次郎, 大庭 幸治, Antony Tin, なかむら ヨシアキ, 坂東 英明, 吉野 孝之, 沖 英次

    日本外科学会定期学術集会抄録集 ((一社)日本外科学会)  126回   WS - 03 2026.04

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Ferroptosis Resistance in the Hepatocellular Carcinoma Microenvironment: Mechanisms and Therapeutic Targeting

    2026.04
    -
    2029.03

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), No Setting

    　View Summary

    肝細胞癌は予後不良の消化器癌の一つであり、非ウイルス性、特にメタボリック症候群に起因する肝細胞癌の割合が増加傾向である。近年、肝細胞癌の薬物療法は進歩を遂げているが、再発をきたすことが多く、薬剤耐性の克服が喫緊の課題である。本研究は「肝細胞癌微小環境における新規細胞死フェロトーシスの抵抗性」が治療抵抗性の本質的要因であるとの仮説に基づき、外科切除標本を用いたマルチオミクス解析、動物モデルによる因果検証と腸内細菌叢変化解析、③全国コホートを用いた数理解析による統合スコア構築を通じて、抵抗性機序を明らかにし、フェロトーシスをターゲットとした治療介入戦略を提示することを目的とする。

  • 直腸癌の個別的リスク評価を目的とした人工知能MRI解析アルゴリズムの確立

    2022.04
    -
    2025.03

    日本学術振興会, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), No Setting

    　View Summary

    局所進行直腸癌は難治疾患であり、治癒を目指すうえで手術、化学療法、放射線療法の複合的治療を適応することは必須要素である。またMRIでのみ評価可能な悪性所見を元に、癌の直腸周囲への拡がりを正確に診断し至適治療を決定する。ただ直腸癌MRI診断は高難度で診断精度向上が必要で、MRI診断精度の不安定さは最適な治療を実施できないことにもつながる。人工知能深層学習で正確な直腸癌MRI診断を実現可能なアルゴリズム確立を目指し、最終的には精密医療の確立へ結びつける。初期データで確認できた癌領域評価の人工知能アルゴリズムを元に、さらに多角的に直腸癌進展を評価可能なアルゴリズムを作成し発展させ上記課題に取り組む。

Page Top ▲

Awards 【 Display / hide 】

  • 第54回高松宮妃癌研究基金 学術賞　受賞

    2025.02

  • Highly Cited Researcher Awards 2024（高被引用論文著者）by Clarivate

    2024.11

  • 第14回JCA-永山賞（旧JCA-CHAAO賞）　受賞

    2024.09

  • 第18回小林がん学術賞　受賞

    2024.06

  • 第20回SGH特別賞（旧佐川特別研究助成賞）受賞

    2022.12

display all >>

Page Top ▲